Latest advances in neoadjuvant therapy for bladder cancer
Keywords:
Urinary Bladder Neoplasms, Neoadjuvant Therapy, Immunotherapy, Biomarkers
Abstract
Cisplatin-based neoadjuvant therapy has shown clear benefits in clinical stage II or IIIA muscle invasive bladder cancer (MIBC), achieving an impact in progression-free survival and overall survival. This updated review focuses on neoadjuvant therapy for MIBC, including the current recommendations from international and/or local practice guidelines, as well as studies of new therapeutic agents (immunotherapy, targeted therapy), on top of research on potential biomarkers that may predict response to immunotherapy.
Downloads
Download data is not yet available.
Published
2022-05-09
How to Cite
1.
Rioja P, Valencia G, Morante Z, Paz R, Vallejos H, Fuentes H, Neciosup S. Latest advances in neoadjuvant therapy for bladder cancer. Acta Med Peru [Internet]. 2022May9 [cited 2024Dec.25];39(1). Available from: http://54.39.98.165/index.php/AMP/article/view/2201
Section
REVIEW
1.png)
.png){kind=logo}
